This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurogenetics  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic

Arch Neurol. 1999;56:273-275.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

X-LINKED adrenoleukodystrophy (ALD)^1-2 is a disorder with widely varying phenotypes. These range from the rapidly progressive childhood cerebral form, which often leads to severe disability and death by age 10 years, to the slowly progressive adrenomyeloneuropathy, which manifests most commonly between ages 20 and 30 years and may be compatible with survival to the eighth and even ninth decade. It may also present as primary adrenocortical insufficiency without demonstrable nervous system involvement. All phenotypes co-occur frequently within the same nuclear family. The milder adult phenotype is often misdiagnosed as multiple sclerosis or as a spastic paraparesis of unknown cause. It is now recognized that these milder adult variants are as common or even more common than the severe childhood form.

The principal biochemical abnormality in ALD is the accumulation of unbranched saturated very long chain fatty acids (VLCFAs) with carbon chain lengths of 24 and 26. Very long chain fatty . . . [Full Text of this Article]

RELATED ARTICLE

Mutational Analysis and Genotype-Phenotype Correlation of 29 Unrelated Japanese Patients With X-linked Adrenoleukodystrophy
Hiroki Takano, Ryoko Koike, Osamu Onodera, Ryogen Sasaki, and Shoji Tsuji
Arch Neurol. 1999;56(3):295-300.
ABSTRACT | FULL TEXT